Aberrant Promoter CpG Methylation Is a Mechanism for Impaired PHD3 Expression in a Diverse Set of Malignant Cells
2011

How Cancer Cells Silence PHD3 Expression

Sample size: 6 publication 10 minutes Evidence: moderate

Author Information

Author(s): Trenton L. Place, Matthew P. Fitzgerald, Sujatha Venkataraman, Sabine U. Vorrink, Adam J. Case, Melissa L. T. Teoh, Frederick E. Domann

Primary Institution: The University of Iowa

Hypothesis

The study investigates whether aberrant methylation of the PHD3 promoter is responsible for its silencing in various cancer cell lines.

Conclusion

PHD3 expression is silenced by aberrant CpG methylation in several human carcinoma cell lines, which prevents its upregulation under hypoxic conditions.

Supporting Evidence

  • PHD3 mRNA expression was nearly undetectable in certain cancer cell lines.
  • Treatment with a demethylating agent significantly increased PHD3 expression.
  • Hypermethylation of the PHD3 promoter was observed in multiple cancer cell lines.

Takeaway

Some cancer cells don't make a protein called PHD3 because a part of their DNA that tells them to make it is turned off. This can happen because of a process called methylation.

Methodology

The study used bisulfite sequencing and methylated DNA enrichment procedures to analyze PHD3 promoter methylation in various cancer cell lines.

Limitations

The study did not find PHD3 promoter methylation in primary human prostate tumors, suggesting that the findings may not apply to all cancer types.

Participant Demographics

The study analyzed various human carcinoma cell lines, including prostate, breast, melanoma, and renal cancer cells.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0014617

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication